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eripheral Blood CD31
ells for the Treatment of
schemic Vascular Disease*
obert D. Simari, MD, Rajiv Gulati, MD, PHD
ochester, Minnesota
he past decade has witnessed an unprecedented rapidity of
rogression from laboratory findings to clinical trials in the
eld of cell therapy for ischemic disease. Trials have been
ompleted, or are currently ongoing, in patients with acute
yocardial infarction, chronic ischemic heart disease, non-
schemic cardiomyopathy, and peripheral arterial disease.
uch of the original pre-clinical data that underpinned
hese clinical trials can be attributed to Dr. Jeffrey Isner and
is group in Boston who demonstrated that peripheral
lood mononuclear cells (PBMCs) were capable of assum-
ng some features of endothelial cells after brief periods of
ulture (1,2). They originally referred to these cells as
See page 593
ndothelial progenitor cells, on the assumption that the cells
enerated were both endothelial in nature and derived from
mmature circulating precursors of bone marrow origin.
hereas subsequent detailed evaluation by a variety of
roups has since suggested these cells to be neither purely
ndothelial nor progenitor in nature (3–5), animal studies
ave consistently demonstrated that administration of
BMC subsets or cells cultured from PBMCs promotes
ngiogenesis in ischemic myocardium or limbs in addition
o preserving tissue function.
There have been few head-to-head studies comparing
herapeutic efficacy of different cell populations. Acknowl-
dging this, if one interprets the available data to indicate no
lear-cut advantage of 1 cell type over another, then the ease
y which 1 cell type can be translated to the clinical arena
ecomes highly relevant. Thus, bone marrow harvesting,
ytokine administration, cell culturing, genetic manipula-
ion, and such must be regarded as barriers to clinical
ranslation and the case for such manipulations would need
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ollege of Cardiology.m
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he authors have reported that they have no relationships to disclose.o be strong if easier and quicker cell preparation strategies
ere equally efficacious. Recently, delivery of granulocyte
olony stimulating factor mobilized peripheral CD34 cells
as been demonstrated to have important clinical effects in
tudies of intramyocardial delivery in patients with intrac-
able angina (6).
A PBMC cell fraction not requiring in vitro culture
odification or mobilization, but enriched for therapeutic
fficacy, would clearly have clinical appeal. In this issue of
he Journal, Kim et al. (7) report that administration of
uman peripheral blood CD31 cells (without culture),
hen compared with administration of the remaining
D31– fraction or of saline, promote angiogenesis and
lood perfusion in a murine model of limb ischemia as well
s preventing limb loss. It is important to note that the
nvestigators did not include an unselected PBMC group in
his study, so it is not possible to state whether the extra step
f selecting a CD31 fraction would be necessary for
herapeutic effect. Indeed, even administration of CD31–
ells appeared to improve the perfusion ratio of ischemic
imbs when compared with administration of saline alone,
lthough with less effect than CD31 cells. From both a
echanistic and translational perspective, it would be of
nterest to know whether avoiding a cell selection process
ould mitigate the therapeutic potency of noncultured cell
reparations such as reported by Kim et al. (7).
CD31, also known as platelet endothelial cell adhesion
olecule, is a member of the immunoglobulin superfamily
8). The rationale for the choice of CD31 as the discrimi-
atory marker is not entirely clear, but likewise, the choice
f CD31 cells for evaluation in a cell therapy study is not
ew. Indeed, members of the same group reported in 2003,
he therapeutic efficacy of cultured autologous CD31 cells
n a porcine model of ischemic myocardial injury (9). At
hat time, the stated reason for choosing CD31 as a
election marker was the lack of availability of a porcine-
pecific antibody to CD34, a purported marker of progen-
tor phenotype, rationalizing that CD31 would identify a
imilar population of “progenitor cells.” However, the cur-
ent study shows CD34 to be expressed on only a small
raction of the isolated CD31 cells. Further justification
or the use of CD31 as a selection marker is the demon-
tration that culture of these cells in endothelial growth
edia yields a population of cells with similar phenotypic
haracteristics to the original “EPCs” as defined by Kalka et
l. (2). Regardless, the choice of CD31 as a selection marker
as been vindicated by the demonstration of therapeutic
fficacy in both the earlier autologous porcine model and the
urrent murine model of human cell therapy.
Kim et al. (7) also sought to track the fate of delivered
uman CD31 cells and used fluorescent labeling of
D31 cell membranes before administration and in situ
ybridization for the Y chromosome in subsequent tissue
nalysis. Additionally, they stained tissues for endothelial
arkers and utilized 3-dimensional confocal microscopy
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n relation to existing tissue architecture. Evaluation of the
ata suggests that a proportion of administered CD31 cells
xhibited an intimate spatial association with neovessels,
hich is consistent with a supportive role in neovascular-
zation. However, their additional claim that human
D31 cells differentiate to form functional endothelium is
ot supported by the data presented. At the very least, they
ould need to exclude intercellular dye transfer, cells in
ransit, and cell fusion as alternative explanations.
So what is the nature of the CD31 cells administered?
he fluorescent-activated cell sorter profile indicates a
ouble peak, suggesting there may even be 2 populations of
D31 cells. Regardless, a monocytic origin seems likely
or the majority. A number of surface markers including
D31, CD105, and CD141 are shared between endothelial
nd monocytic lineage cells. Moreover, when cultured in
ndothelial growth media, their subsequent phenotype is
onsistent with cultured monocytic lineage cells (3,4) in-
luding staining for lectin and uptake of acetylated low-
ensity lipoprotein, features of both monocytic lineage, and
ndothelial cells. Although there is no convincing evidence
or an endothelial progenitor phenotype in vitro and in vivo,
erhaps their monocytic phenotype explains their therapeu-
ic efficacy. Monocytes play a critical role in neo-
rteriogenesis (10), may drill early tubes in ischemic tissue
11), and are capable of considerable growth factor produc-
ion. Indeed, the investigators demonstrate a marked dif-
erence in expression of growth factor, cell adhesion, and
hemoattraction genes in CD31 versus CD31– cells as well
s demonstrating CD31 cellular formation of tubules with
rolonged culture.
Two aspects of this study are of particular importance for
otential clinical translation. First, it demonstrates the ease
y which a therapeutically relevant cell population can be
btained with the minimum of manipulation. A peripheral
lood draw followed by generation of the appropriate cell
raction via automated methods and readministration by
ercutaneous injection could be accomplished in any num-
er of facilities, at relatively low cost, and with minimal
isruption to existing infrastructure. Second, whereas it
emains to be seen whether the number of cells generated
ould be sufficient for therapeutic effect, the abundance of
he CD31 cell population in peripheral blood is certainly a
trength. If future head-to-head studies indicated that such
K
ycell population was equally efficacious as other leading
ontenders in the cell arena derived from peripheral mobi-
ization or adipose tissue or bone marrow, this would further
trengthen the case for CD31 selection of PBMCs. Thus,
tudies like this one by Kim et al. (7) add to the environ-
ent of rapid translation for cell-based therapies in isch-
mic cardiovascular disease.
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